Altamura A C, Mauri M C, Rudas N, Carpiniello B, Montanini R, Perini M, Scapicchio P L, Hadjchristos C, Carucci G, Minervini M
Department of Clinical Psychiatry, University of Milan, Italy.
Clin Neuropharmacol. 1989;12 Suppl 1:S25-33; S34-7. doi: 10.1097/00002826-198901001-00005.
The aim of this multicenter study was to compare trazodone (TRA) with two reference drugs, amitriptyline (AMI) and mianserin (MIA), under double-blind conditions, in an elderly population, to ascertain age-related patterns for efficacy and tolerability. One hundred six elderly depressed inpatients, ranging in age from 60 to 83 years, diagnosed as having major depression according to DSM-III, were treated with 75 mg AMI (37 patients), 60 mg MIA (33 patients) or 150 mg TRA (36 patients) p.o.t.i.d. for 5 weeks. There were no differences in the clinical outcome among the three groups of patients at the end of the trial, with a significant amelioration (p less than 0.01) for the Hamilton Rating Scale for Depression (HRS-D) and the Geriatric Depression Scale (GDS). TRA showed a lower overall prevalence of side effects than AMI or MIA, particularly for anticholinergic (p = 0.03 vs. AMI) and cardiovascular (p = 0.05 vs. MIA) effects. For these data GDS seems to be most reliable in detecting changes in elderly depressive symptomatology; moreover a comparable therapeutic response (among the three drugs) but a better tolerance for atypical antidepressants, particularly TRA, make advisable the use of the latter drug in the elderly population.
这项多中心研究的目的是在双盲条件下,对老年人群中的曲唑酮(TRA)与两种参比药物阿米替林(AMI)和米安色林(MIA)进行比较,以确定与年龄相关的疗效和耐受性模式。106名年龄在60至83岁之间、根据《精神疾病诊断与统计手册》第三版被诊断为重度抑郁症的老年住院抑郁症患者,分别接受口服75毫克AMI(37例患者)、60毫克MIA(33例患者)或150毫克TRA(36例患者),每日三次,持续5周。试验结束时,三组患者的临床结局没有差异,汉密尔顿抑郁量表(HRS-D)和老年抑郁量表(GDS)均有显著改善(p<0.01)。与AMI或MIA相比,TRA的副作用总体发生率较低,尤其是抗胆碱能作用(与AMI相比,p = 0.03)和心血管作用(与MIA相比,p = 0.05)。基于这些数据,GDS在检测老年抑郁症状变化方面似乎最为可靠;此外,(三种药物之间)具有可比的治疗反应,但非典型抗抑郁药,尤其是TRA,耐受性更好,这使得在老年人群中使用后一种药物是可取的。